Gene Expression Ratio Test Predicts Post-Surgery Outcome in Mesothelioma
Wednesday, April 29th, 2009.
A four-gene expression ratio test prospectively distinguished mesothelioma patients who had a statistically significant longer overall survival from those who had shorter survival, according to researchers from the Brigham and Women’s Hospital.
The team’s previous retrospective studies found that measuring expression ratios of four genes could distinguish between those who have a good prognosis after surgery and those who have a poor prognosis. They thus decided to validate their findings in a prospective study, which is reported in the Journal of the National Cancer Institute in a paper titled “Four-Gene Expression Ratio Test for Survival in Patients Undergoing Surgery for Mesothelioma.”
In the current investigation, they tested the four-gene expression ratio test in 120 patients with mesothelioma who were treated at the hospital and participated in a prospective clinical trial. To evaluate the robustness and reproducibility of the test, the researchers evaluated the test on multiple tumor samples from each patient and used two different microarray platforms and two different biopsy techniques.
The test was able to predict overall survival after adjusting for other clinical factors. The results were consistent for individual patients regardless of the techniques used. When the researchers combined the gene ratio test results with known prognostic factors, they were able to separate patients into high-risk and low-risk groups. The median survival for patients in the high-risk group was 6.9 months compared with 31.9 months in the low-risk group.
« Mesothelioma News Main Page.
Most Recent in
Asbestos & Mesothelioma Studies
- 03/22/11 - Smoking and Lung Cancer Not the End of the Story: Asbestos and Smoking Create an Incredibly Deadly Combination
- 04/20/10 - MolMed starts Phase III trial of NGR-hTNF in mesothelioma
- 04/13/10 - microRNAs Shown To Have Powerful Potential as Diagnostic and Prognostic Markers In A Variety Of Cancer Indications
- 03/26/10 - Bionomics To Initiate BNC105 Phase II Trial In Mesothelioma Patients
- 03/15/10 - New NCCN Guidelines™ for Malignant Pleural Mesothelioma Presented at Annual Conference
Most Recent in
Mesothelioma Blood Test
- 04/29/09 - Gene Expression Ratio Test Predicts Post-Surgery Outcome in Mesothelioma
- 12/29/08 - Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
- 11/02/07 - Fujirebio Diagnostics Honored with Pioneer Award from Meso Foundation: MESOMARK® Test Recognized for Monitoring Patients with Asbestos-linked Cancer
- 04/23/07 - NYU Medical Center Partners With Rosetta Genomics to Develop a Line of Diagnostic Tools for Lung and Mesothelioma Cancers
- 03/26/07 - CISBIO Announces FDA Approval of MESOMARK®; Assay Now Available to Physicians in the U.S. for Monitoring Patients with Mesothelioma
Most Recent in
Novel Treatments & Drugs
- 10/12/10 - Raltitrexed (Tomudex®) in Combination With Cisplatin in the Treatment of MPM Improves Overall Survival Compared to Treatment With Cisplatin Alone
- 04/20/10 - MolMed starts Phase III trial of NGR-hTNF in mesothelioma
- 04/13/10 - microRNAs Shown To Have Powerful Potential as Diagnostic and Prognostic Markers In A Variety Of Cancer Indications
- 03/26/10 - Bionomics To Initiate BNC105 Phase II Trial In Mesothelioma Patients
- 04/29/09 - Gene Expression Ratio Test Predicts Post-Surgery Outcome in Mesothelioma
You can follow any responses to this entry through the RSS 2.0 feed.
You can skip to the end and leave a response. Pinging is currently not allowed.
